Table 2B.

Uterine fibroid logistic regression analysis, p-values are Bonferroni adjusted.

Odds	95 % CI lower limit	95 % CI upper limit	Standard Error	Survey question topic	Class ID	p-value	Mean prevalence	Sd prevalence	Missingness rate	Mean VIF
40.20	20.58	60.94	0.25	Hysterectomy	MAXO:0001058	10.20E-08*	0.20	0.40	0.00	20.04
50.01	20.47	10.94	0.38	Uterine polyps	MONDO:0006195	10.90E-05 *	0.06	0.24	0.00	10.27
30.71	10.77	80.35	0.39	Omeprazole	CHEBI:7772	80.29E-04 *	0.05	0.22	0.00	10.62
10.69	10.16	20.49	0.20	Iron deficiency anemia	HP:0001891	70.04E-03	0.24	0.43	0.00	10.26
10.71	10.16	20.54	0.20	Hypertension	HP:0000822	70.27E-03	0.29	0.45	0.00	10.92
10.70	10.13	20.56	0.21	Menopause	GO:0042697	10.04E-02	0.50	0.50	0.01	20.10
10.69	10.12	20.54	0.21	Ovarian cysts	HP:0000138	10.19E-02	0.22	0.41	0.00	10.41
10.22	10.04	10.43	0.08	Orange consumption	ECTO:0070029	10.37E-02	20.53	10.05	0.02	10.63
10.69	10.07	20.68	0.23	Magnesium supplementation	ECTO:9000210	20.46E-02	0.16	0.37	0.01	10.43
20.58	10.11	60.34	0.44	Kidney infection	HP:0012330	30.25E-02	0.05	0.22	0.01	10.30
10.42	10.02	10.96	0.17	Vitamin D supplementation	ECTO:9000133	30.53E-02	0.51	0.50	0.01	10.55
30.97	10.12	180.82	0.70	Duloxetine	CHEBI:36796	40.82E-02	0.01	0.12	0.00	10.40
0.57	0.32	10.00	0.29	Gallbladder disease	MONDO:0005281	40.91E-02	0.10	0.31	0.01	10.42

^*P-values < 0.005.